Cerevel Therapeutics began trading on the Nasdaq.
Through a definitive merger agreement, BridgeBio acquired 36.3 percent of Eidos Therapeutics’ outstanding common stock that it did not already own.
Netherlands-based Mylan is buying the intellectual property and commercialization rights to Aspen Pharmacare’s thrombosis business in Europe for €641.9 million ($757.3 million).
Cambridge, Massachusetts-based Yumanity Therapeutics and Boston-based Proteostasis Therapeutics announced plans to merge. The combined company will operate after the deal as Yumanity Therapeutics, and will focus on protein misfolding and neurodegenerative diseases.
Shares of Gilead Sciences rose following a report that the company was approached by U.K. pharma giant AstraZeneca regarding a potential merger.
Neurotrope and Metuchen Pharmaceuticals announced the companies have merged in an all-stock deal to form Petros Pharmaceuticals, which is focused on men’s health conditions.
As Tocagen heads into a reverse merger with privately held Forte Biosciences, San Diego-based Denovo Biopharma swooped in to snap up that company’s retroviral replicating vector platform (RRV), including an asset that stumbled in a Phase III study that Denovo believes still has some life.
Social distancing measures for COVID-19 are having an impact on the planned merger of Mylan and Pfizer’s off-patent business, Upjohn.
AbbVie and Allergan are closer to completing the $63 billion combination of the two companies after entering into a consent decree agreement with the Federal Trade Commission that commits them to a previously announced divestiture of products ahead of the merger.
As Allergan and AbbVie continue to move forward with their unification, a group of unions and consumer organizations have banded together in opposition to the $63 billion merger citing concerns that the business combination will create a monopoly and harm competition.
